보고서 요약(국문)

개요
전 세계 차세대 면역 치료제 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 차세대 면역 치료제 시장은 여러 요인의 영향으로 상당한 성장과 변화를 경험해 왔습니다. 수년간의 종양학 임상 경험을 통해 암 면역 치료가 전례 없는 치료 효과를 제공한다는 것이 입증되었습니다. 그러나 안타깝게도 현재 면역 치료의 혜택을 받는 환자는 소수에 불과합니다. 최근 RNA 지질 나노입자는 면역 활성화를 위한 다재다능한 도구로 주목받고 있습니다.
특히 개발도상국을 중심으로 한 정부 협력, 투자 및 연구는 단일클론 항체 또는 면역 체크포인트 억제제와 같은 신약의 활용을 촉진하고 전 세계 차세대 면역 치료제 시장을 활성화할 것입니다. 여러 연구자들이 이러한 혁신적인 면역 치료제를 개발하고 있으며 현재 연구가 진행 중입니다.

시장 동향: 성장 동력 및 제약 요인
협력 및 인수 증가
선진국들은 높은 투자, 소득 수준, 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 차세대 면역 치료제에 대한 연구가 활발해짐에 따라 수요가 증가하고 있습니다. 다양한 국가 간의 협력, 인수, 그리고 기술 발전을 동반한 신제품 출시가 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2022년 11월 17일, CytomX의 Probody 플랫폼과 Regeneron의 Veloci-Bi 이중특이항체 개발 플랫폼을 활용하여 조건부 활성화 이중특이항체 항암 치료제 개발을 위해 CytomX Therapeutics, Inc.와 Regeneron Pharmaceuticals, Inc.는 협력 및 라이선스 계약을 체결했습니다. 전략적으로, 양사는 CytomX의 생물학적 마스킹 기술을 활용하여 종양 미세환경 내 프로테아제에 의해 활성화될 때까지 비활성 상태를 유지하는 Regeneron의 이중특이항체를 개발하는 것을 목표로 하고 있습니다.

또한, 2022년 6월 2일, 이매틱스(Immatics N.V.)와 브리스톨 마이어스 스큅(Bristol Myers Squibb)은 다양한 동종 표준 TCR-T 및/또는 CAR-T 제품 개발을 모색하기 위해 전략적 파트너십을 확대했습니다. 이매틱스는 T세포 재지향성 암 면역 치료제 발굴 및 개발에 주력하는 임상 단계 바이오제약 회사입니다.
더불어, 다양한 연구 목적을 위한 신기술 활용 증가와 신제품 출시가 차세대 면역 치료제 시장 성장을 견인하는 주요 요인이 될 것입니다. 암 발병률 증가와 혁신적인 치료제 개발 연구 확대가 그 예입니다.
면역 치료 관련 부작용
면역 치료의 부작용으로 면역 체계가 건강한 세포를 공격할 수 있습니다. 이러한 "면역 관련 이상 반응"은 때때로 부작용으로 알려져 있으며, 치료 과정 중 언제든지 또는 드물게는 치료 종료 후에도 발생할 수 있습니다. 면역 치료는 다양한 부작용을 동반합니다. 면역 체크포인트 억제제 부작용으로 면역 세포뿐만 아니라 건강한 신체 조직도 면역 세포의 공격을 받는 경우가 흔합니다. 이러한 과정을 염증이라고 합니다.
CAR T-세포 치료의 일반적인 부작용은 감염입니다. 면역 체계의 감염 저항력이 약화될 수 있기 때문에 주입 직후에 감염이 자주 발생합니다. 발열, 메스꺼움, 피로, 두통, 허약감, 전반적인 불편감 등이 감염의 징후입니다.
세그먼트 분석
전 세계 차세대 면역 치료제 시장은 면역 치료제 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
단클론 항체 부문은 시장 점유율의 약 32%를 차지했습니다.
단클론 항체로 알려진 면역 체계 단백질은 실험실에서 생산됩니다. 인체는 자연적으로 항체를 생성하며, 이 항체는 면역 체계가 박테리아 및 바이러스와 같은 병원성 미생물을 식별하고 제거하도록 돕습니다. 암 치료에는 단클론 항체가 자주 사용됩니다.
표적 암 치료의 한 형태로, 특정 표적과 상호 작용하도록 만들어집니다. 특정 단클론 항체는 면역 체계를 활성화하여 신체가 암과 싸우도록 돕기 때문에 면역 요법에도 사용됩니다. 예를 들어, 특정 단클론 항체는 암세포에 표지를 붙여 면역 체계가 암세포를 더 쉽게 식별하고 제거하도록 돕습니다.
2022년 12월 21일, 미국 식품의약국(FDA)은 전신 코르티코스테로이드를 투여받고 추가 산소 공급, 비침습적 및 침습적 기계 환기 또는 체외막 산소 공급(ECMO)이 필요한 성인 코로나19 환자의 치료를 위해 제넨텍의 액템라(토실리주맙) 정맥주사제를 승인했습니다. FDA 승인을 받은 최초의 코로나19 치료제인 액템라는 60분 동안 1회 정맥 주입하는 것이 권장됩니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 38%를 차지했습니다.
차세대 면역 요법에 대한 의료 수요 증가로 인해 북미 제조업체들은 사업 확장의 기회를 갖고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 차세대 면역 치료제에 대한 수요를 견인하고 있습니다.
의료비 지출 증가, 연구 개발 확대, 기술 및 다양한 의약품 개발, 그리고 이 지역 전반에 걸친 바이오 제약 또는 생명공학 기업 설립 증가는 차세대 면역 치료제 시장 점유율 성장에 기여하고 있습니다. 다양한 신규 승인 치료법에 대한 인식이 높아짐에 따라 이 지역의 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 차지하는 지배적인 위치를 더욱 뒷받침합니다.
북미는 미국을 중심으로 글로벌 차세대 면역 치료제 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 첨단 기술 발전에 대한 집중적인 투자는 미국 내 차세대 면역 치료제 수요를 촉진했습니다. 미국은 차세대 면역 치료제 수요를 자극하는 여러 정책 및 연구를 적극적으로 추진해 왔습니다.

COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 차세대 면역항암제 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄, 공급망 차질, 경제 활동 위축에 직면하면서 다양한 치료제의 주요 소비처인 제약 부문은 심각한 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치는 전 세계적으로 여러 사업에 영향을 미쳤습니다.
주요 의료 및 생명공학 산업은 운영을 중단하고 COVID-19 관리에 집중하면서 차세대 면역항암제 수요가 급감했습니다. 그러나 현재 여러 연구가 재개되었고 기업들은 제품 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로 팬데믹이 차세대 면역항암제 시장에 미치는 영향은 비교적 완만할 것으로 예상되며, 혁신적인 면역항암제에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.

주요 동향
• 2023년 9월 11일, 미국 식품의약국(FDA)은 화이자(Pfizer Inc.)와 바이오엔텍(BioNTech SE)이 개발한 오미크론 XBB.1.5 변형 단가 코로나19 백신에 대해 12세 이상 성인 대상 보충 생물학적 제제 허가 신청(SBL)을 승인하고, 6개월~11세 소아 대상 긴급 사용 승인을 부여했습니다. 이는 화이자와 바이오엔텍이 공동으로 발표했습니다.
• 2023년 1월 9일, 3T 바이오사이언스(3T Biosciences)와 베링거인겔하임(Boehringer Ingelheim)은 미충족 환자 수요를 획기적으로 해결할 차세대 항암제를 발굴 및 개발하기 위한 전략적 파트너십 및 라이선스 계약을 체결했습니다. 베링거인겔하임의 암세포 표적 및 면역세포 표적 화합물을 결합한 이중 접근 방식에 3T 바이오사이언스의 독보적인 3T-TRACE(T-세포 수용체 항원 및 교차 반응성 엔진) 발굴 플랫폼을 결합하여 파이프라인을 더욱 강화할 예정입니다.

• 2021년 6월 4일, 소렌토 테라퓨틱스(Sorrento Therapeutics, Inc.)는 유도만능줄기세포(iPSC)에서 유래한 자연살해(NK) 세포를 활용한 새로운 세포 기반 치료제 개발을 위해 스웨덴 스톡홀름에 위치한 카롤린스카 연구소(Karolinska Institutet, KI) 의학과 산하 NextGenNK 역량센터 소속 연구진과 추가 협력 계약을 체결했습니다. 차세대 NK 세포 기반 암 면역 치료제 개발을 위한 NextGenNK 역량센터는 소렌토와 KI의 파트너십으로 운영됩니다.

경쟁 구도
주요 글로벌 시장 참여 기업으로는 리제네론 파마슈티컬스(Regeneron Pharmaceuticals Inc.), 아스트라제네카(AstraZeneca), 브리스톨-마이어스 스큅(Bristol-Myers Squibb Company), 화이자(Pfizer Inc.), 길리어드 사이언스(Gilead Sciences, Inc.), 베링거 인겔하임 인터내셔널(Boehringer Ingelheim International GmbH), 매크로제닉스(MacroGenics, Inc.), 메레오 바이오파마 그룹(Mereo Biopharma Group PLC), 소렌토 테라퓨틱스(Sorrento Therapeutics), 바이오엔텍(BioNTech SE) 등이 있습니다.

보고서 구매 이유

• 면역요법 유형, 투여 경로, 유통 채널 및 지역별 차세대 면역요법 시장의 세분화 현황을 시각화하고 주요 기업 및 주요 업체를 파악할 수 있습니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

• 차세대 면역요법 시장의 모든 세그먼트에 대한 다양한 데이터가 담긴 엑셀 파일을 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

차세대 면역요법 시장 보고서는 약 61개의 표, 59개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global next generation immunotherapies market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global next generation immunotherapies market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Years of oncology clinical experience have shown that cancer immunotherapy offers unheard-of therapeutic advantages. Tragically, only a small percentage of patients benefit from immunotherapies today. Recently, RNA lipid nanoparticles have become versatile instruments for immune activation.
Government partnerships, investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like monoclonal antibodies or immune checkpoint inhibitors and boost the global next generation immunotherapies market. The respective innovative immunotherapies are being developed by several researchers and currently are being studied.
Market Dynamics: Drivers & Restraints
Growing collaborations and acquisitions
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for next generation immunotherapies owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.
On November 17, 2022, in order to develop conditionally-activated investigational bispecific cancer therapies using CytomX's Probody helpful platform and Regeneron's Veloci-Bi bispecific antibody development platform, CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. collaborated and agreed to a licensing agreement. Strategically, the team aims to create exploratory Regeneron bispecifics that are dormant until activated by proteases in the microenvironment of tumors by utilizing CytomX's biologic masking techniques.
Additionally, on June 2, 2022, Immatics N.V. and Bristol Myers Squibb have broadened their strategic partnership to explore the development of numerous allogeneic standard TCR-T and/or CAR-T products. Immatics N.V. is a clinical-stage biopharmaceutical business engaged in the discovery and creation of T cell-redirecting cancer immunotherapies.
Furthermore, the rising utilization of novel technology and product launches for the several research purposes. Rising oncology cases and increasing research for innovative treatment product development will be a major factor driving the growth of the next generation immunotherapies market.
Side effects associated with the immunotherapy
The immune system may assault healthy cells as a side effect of immunotherapy. "Immune-related adverse effects," sometimes known as side effects, may result from this. These could occur at any point over the course of the therapy or occasionally even after finishing immunotherapy. Immunotherapy comes with a variety of adverse effects. Immune cells as well as healthy bodily tissues are frequently attacked by immune cells as immune checkpoint inhibitor side effects. This process is known as inflammation.
A typical side effect of CAR T-cell treatment is infection. They frequently occur immediately after the infusion because the immune system's ability to combat infections may be compromised. Fever, nausea, exhaustion, headaches, weakness, and an overall sensation of discomfort are all signs of infection.
Segment Analysis
The global next generation immunotherapies market is segmented based on immunotherapy type, route of administration, distribution channel and region.
Monoclonal Antibodies segment accounted for approximately 32% of market share
Immune system proteins known as monoclonal antibodies are produced in a laboratory. The body naturally produces antibodies, which assist the immune system in identifying pathogenic microorganisms like bacteria and viruses and marking them for eradication. Cancer treatment frequently makes use of monoclonal antibodies.
As a form of targeted cancer therapy, they are created to interact with particular targets. Certain monoclonal antibodies are also used in immunotherapy because they assist the body fight cancer by activating the immune system. As an illustration, certain monoclonal antibodies label cancer cells to help the immune system more easily identify and eliminate them.
On December 21, 2022, the U.S. Food and Drug Administration (FDA) has approved Genentech's Actemra (tocilizumab) intravenous (IV) for the management of COVID-19 in being treated adult patients who receive systemic corticosteroids and need additional oxygen, non-invasive and invasive mechanical ventilation, or oxygenation through extracorporeal membranes (ECMO). Actemra, the first monoclonal antibody approved by the FDA to treat COVID-19, is advised for use as a single, 60-minute IV infusion.
Geographical Penetration
North America accounted for around 38% of market share in 2022
Due to the rising need for next generation immunotherapies in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for next generation immunotherapies.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of medicines, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of next generation immunotherapies market share of this region. The market in this area is growing as people become more aware of various novel approved therapies. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global next generation immunotherapies market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for next generation immunotherapies in the U.S. United States have been proactive in executing several initiatives or researches, stimulating next generation immunotherapies demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global next generation immunotherapies market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various therapies, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for next generation immunotherapies. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global next generation immunotherapies market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative immunotherapy type.
Key Developments
• On September 11, 2023, The U.S. Food and Drug Administration (FDA) has authorized the supplemental biologics license application for people 12 years of age and older and granted emergency use authorization for people 6 months to 11 years of age for the companies' monovalent COVID-19 vaccine modified for Omicron XBB.1.5. This was announced by Pfizer Inc. and BioNTech SE.
• On January 9, 2023, in order to find and develop next-generation cancer medicines that will significantly address unmet patient needs, 3T Biosciences and Boehringer Ingelheim have engaged into an strategic partnership and licensing agreement. Boehringer Ingelheim's two-pronged investigation approach combining cancer cell-directed and immune cell-targeting compounds will be combined with 3T Biosciences' unparalleled 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform, further strengthening the company's pipeline.
• On June 4, 2021, in order to develop novel cell-based therapeutics using natural killer ("NK") cells generated from induced pluripotent stem cells ("iPSCs"), Sorrento Therapeutics, Inc. has entered into another collaborative agreement with research groups affiliated with the NextGenNK Competence Center at the Department of Medicine, Huddinge, Karolinska Institutet in Stockholm, Sweden. The Competence Center for the creation of next-generation cancer immunotherapies based on NK cell (referred to as "NextGenNK") is a partnership between Sorrento and KI.
Competitive Landscape
The major global players in the market include Regeneron Pharmaceuticals Inc., AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, MacroGenics, Inc., Mereo Biopharma Group PLC, Sorrento Therapeutics and BioNTech SE.
Why Purchase the Report?
• To visualize the global next generation immunotherapies market segmentation based on immunotherapy type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of next generation immunotherapies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global next generation immunotherapies market report would provide approximately 61 tables, 59 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Immunotherapy Type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing collaborations and acquisitions
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the immunotherapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Immunotherapy Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
7.1.2. Market Attractiveness Index, By Immunotherapy Type
7.2. Monoclonal Antibodies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Immune Checkpoint Inhibitors
7.4. Non-specific Immunotherapies
7.4.1. Cytokines
7.4.2. Bacillus Calmette-Guerin (BCG)
7.5. Antibody Drug Conjugate
7.6. Cellular Therapy
7.6.1. T-Cell Therapy
7.6.2. B-Cell Therapy
7.7. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Regeneron Pharmaceuticals Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AstraZeneca
12.3. Bristol-Myers Squibb Company
12.4. Pfizer Inc.
12.5. Gilead Sciences, Inc.
12.6. Boehringer Ingelheim International GmbH
12.7. MacroGenics, Inc.
12.8. Mereo Biopharma Group PLC
12.9. Sorrento Therapeutics
12.10. BioNTech SE
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Regeneron Pharmaceuticals Inc., 4. Key Developments, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, MacroGenics, Inc., Mereo Biopharma Group PLC, Sorrento Therapeutics, BioNTech SE

표 목록 (Tables)

List of Tables

Table 1 Global Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Next Generation Immunotherapies Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Next Generation Immunotherapies Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Next Generation Immunotherapies Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2021-2030 (US$ Million)

Table 7 Global Next Generation Immunotherapies Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Next Generation Immunotherapies Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Next Generation Immunotherapies Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Next Generation Immunotherapies Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Next Generation Immunotherapies Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Next Generation Immunotherapies Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2021-2030 (US$ Million)

Table 14 North America Next Generation Immunotherapies Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Next Generation Immunotherapies Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Next Generation Immunotherapies Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2021-2030 (US$ Million)

Table 18 South America Next Generation Immunotherapies Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Next Generation Immunotherapies Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Next Generation Immunotherapies Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2021-2030 (US$ Million)

Table 22 Europe Next Generation Immunotherapies Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Next Generation Immunotherapies Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Next Generation Immunotherapies Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Next Generation Immunotherapies Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Next Generation Immunotherapies Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Next Generation Immunotherapies Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Next Generation Immunotherapies Market Value, By Immunotherapy Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Next Generation Immunotherapies Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Next Generation Immunotherapies Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Regeneron Pharmaceuticals Inc.: Overview

Table 33 Regeneron Pharmaceuticals Inc.: Product Portfolio

Table 34 Regeneron Pharmaceuticals Inc.: Key Developments

Table 35 AstraZeneca: Overview

Table 36 AstraZeneca: Product Portfolio

Table 37 AstraZeneca: Key Developments

Table 38 Bristol-Myers Squibb Company: Overview

Table 39 Bristol-Myers Squibb Company: Product Portfolio

Table 40 Bristol-Myers Squibb Company: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Gilead Sciences, Inc.: Overview

Table 45 Gilead Sciences, Inc.: Product Portfolio

Table 46 Gilead Sciences, Inc.: Key Developments

Table 47 Boehringer Ingelheim International GmbH: Overview

Table 48 Boehringer Ingelheim International GmbH: Product Portfolio

Table 49 Boehringer Ingelheim International GmbH: Key Developments

Table 50 MacroGenics, Inc.: Overview

Table 51 MacroGenics, Inc.: Product Portfolio

Table 52 MacroGenics, Inc.: Key Developments

Table 53 Mereo Biopharma Group PLC: Overview

Table 54 Mereo Biopharma Group PLC: Product Portfolio

Table 55 Mereo Biopharma Group PLC: Key Developments

Table 56 Sorrento Therapeutics: Overview

Table 57 Sorrento Therapeutics: Product Portfolio

Table 58 Sorrento Therapeutics: Key Developments

Table 59 BioNTech SE: Overview

Table 60 BioNTech SE: Product Portfolio

Table 61 BioNTech SE: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 2 Global Next Generation Immunotherapies Market Share, By Immunotherapy Type, 2022 & 2030 (%)

Figure 3 Global Next Generation Immunotherapies Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Next Generation Immunotherapies Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Next Generation Immunotherapies Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Next Generation Immunotherapies Market Y-o-Y Growth, By Immunotherapy Type, 2022-2030 (%)

Figure 7 Monoclonal Antibodies Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 8 Immune Checkpoint Inhibitors Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 9 Non-specific Immunotherapies Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 10 Antibody Drug Conjugate Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 11 Cellular Therapy Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 12 Others Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 13 Global Next Generation Immunotherapies Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Oral Route of Administration in Global Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 15 Parenteral Route of Administration in Global Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 16 Global Next Generation Immunotherapies Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 20 Global Next Generation Immunotherapies Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 24 South America Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 26 North America Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 27 North America Next Generation Immunotherapies Market Share, By Immunotherapy Type, 2022 & 2030 (%)

Figure 28 North America Next Generation Immunotherapies Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Next Generation Immunotherapies Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Next Generation Immunotherapies Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 32 South America Next Generation Immunotherapies Market Share, By Immunotherapy Type, 2022 & 2030 (%)

Figure 33 South America Next Generation Immunotherapies Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Next Generation Immunotherapies Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Next Generation Immunotherapies Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Next Generation Immunotherapies Market Share, By Immunotherapy Type, 2022 & 2030 (%)

Figure 38 Europe Next Generation Immunotherapies Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Next Generation Immunotherapies Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Next Generation Immunotherapies Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Next Generation Immunotherapies Market Share, By Immunotherapy Type, 2022 & 2030 (%)

Figure 43 Asia-Pacific Next Generation Immunotherapies Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Next Generation Immunotherapies Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Next Generation Immunotherapies Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Next Generation Immunotherapies Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Next Generation Immunotherapies Market Share, By Immunotherapy Type, 2022 & 2030 (%)

Figure 48 Middle East & Africa Next Generation Immunotherapies Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Next Generation Immunotherapies Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Regeneron Pharmaceuticals Inc.: Financials

Figure 51 AstraZeneca: Financials

Figure 52 Bristol-Myers Squibb Company: Financials

Figure 53 Pfizer Inc.: Financials

Figure 54 Gilead Sciences, Inc.: Financials

Figure 55 Boehringer Ingelheim International GmbH: Financials

Figure 56 MacroGenics, Inc.: Financials

Figure 57 Mereo Biopharma Group PLC: Financials

Figure 58 Sorrento Therapeutics: Financials

Figure 59 BioNTech SE: Financials

글로벌 차세대 면역 치료제 시장 – 2023-2030

Global Next Generation Immunotherapies Market -2023-2030